Re:U.S. lawmakers ask Gilead to justify hepatitis C drug's $...
by boomlinde on Friday April 04, 2014 @04:04AM
(#7529946)
According to the IFPMA, on average, a sixth of all sales in the U.S. pharmaceutical industry revenue is spent on R&D. To put things in perspective, according to WHO, this is roughly half of what they spend on marketing.
http://www.ifpma.org/fileadmin/content/Publication/2011/2011... http://www.who.int/trade/glossary/story073/en/
Re:U.S. lawmakers ask Gilead to justify hepatitis C drug's $...
by coderaptor on Friday April 04, 2014 @02:44AM
(#7529723)
But, in the end, still market-bearable costs. Maybe we'd see a reduction of the costs of doing research if there weren't so much tax-payer and insurance money involved today.
They're not related to production costs; they're related to the cost of researching drugs in the future. That is, prices determine what pharma companies will be able to do later on.
Not saying I agree with that, but that's how it is.